A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
Chunyin Gu, Xiaodan Cao, Zongda Wang, Xue Hu, Yanfeng Yao, Yiwu Zhou, Peipei Liu, Xiaowu Liu, Ge Gao, Xiao Hu, Yecheng Zhang, Zhen Chen, Li Gao, Yun Peng, Fangfang Jia, Chao Shan, Li Yu, Kunpeng Liu, Nan Li, Weiwei Guo, Guoping Jiang, Juan Min, Jianjian Zhang, Yang Lü, Meng Shi, Tianquan Hou, Yanan Li, Weichen Liang, Guoqiao Lu, Congyi Yang, Yuting Wang, Kaiwen Xia, Xiao Zheng, Jianhua Xue, Xueyi Huang, Xin Chen, Haixia Ma, Donglin Song, Zhongzong Pan, Xueping Wang, Haibing Guo, Liang Hong, Zhiming Yuan, Wuxiang Guan, Su-Jun Deng
Abstract
blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants, including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical-stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.